Metabolic effects of metformin in patients with type 2 diabetes mellitus and new coronavirus infection

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Limited contraindications for use; lack of stimulation of insulin secretion; weight gain and an extremely low risk of hypoglycemic episodes determine the relevance of the use of metformin as a first-line drug in the treatment of type 2 diabetes mellitus (DM2). The potential of metformin is not limited to its use in DM2. Numerous studies determining the pleiotropic effects of metformin have expanded the range of use of this drug. The article presents various metabolic properties of metformin; which have a beneficial effect on the pathogenesis of various pathological conditions; a new coronavirus infection.

 

全文:

受限制的访问

作者简介

Inessa Zhurtova

Kabardino-Balkarian State University n.a. Kh.M. Berbekov

编辑信件的主要联系方式.
Email: zhin07@mail.ru
ORCID iD: 0000-0003-0668-1073

Dr. Sci. (Med.), Professor at the Department of Faculty Therapy

俄罗斯联邦, Nalchik

A. Gubachikova

Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0000-0002-0017-011X

Department of Faculty Therapy; Medical Academy

俄罗斯联邦, Nalchik

L. Aramisova

Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0000-0001-8105-4235

Department of Faculty Therapy; Medical Academy

俄罗斯联邦, Nalchik

L. Anaeva

Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0000-0001-8421-8661

Department of Faculty Therapy, Medical Academy

俄罗斯联邦, Nalchik

H. Abdul Moati

Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru

Department of Faculty Therapy, Medical Academy

俄罗斯联邦, Nalchik

参考

  1. Sterne J. Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanidine. (N.N.D.G.). Maroc Med. 1957;36:1295–96.
  2. Bailey S.D. Metformin: A Historical review. Diabetol. 2017;60:1566–76. doi: 10.1007/s00125-017-4318-z.
  3. Rena G.; Hardy D.G.; Pearson E.R. Mechanisms of action of metformin. Diabetol. 2017;60(9):1577–85.
  4. Inzucchi S.E. Isn’t it time to change the paradigm of type 2 diabetes treatment? no! Diab Care. 2017;40(8):1128–32.
  5. Curd F.H.S.; Davey D.G.; Rose F.L. Studies of synthetic antimalarial drugs. Some derivatives of biguanide as new types of antimalarial substances with both therapeutic and causal-prophylactic activity. Ann Trope Honey Parasitol. 1945;39:208–16.
  6. Garcia E. 1949 Flumamine. Untraced publication from the Philippines. Cited by Sterne J in an interview (April 4; 1996) for Merck-Lipha published in Glucophage; serving diabetology for 40 years. Pasik C (ed). Lyon: Groupe Lipha; 1997;21:29.
  7. Сердечно–сосудистые заболевания и сахарный диабет – междисциплинарный подход к лечению пациента. [Cardiovascular diseases and diabetes mellitus an interdisciplinary approach to patient treatment. (In Russ.)]. URL: https://www.endocrincentr.ru/specialists/education/obrazovanie-v-nmic-endokrinologii/nauchno-prakticheskie–meropriyatiya/obuchayushchie–seminary-i-lekcii/serdechno–sosudistye-zabolevaniya-i-saharnyy-diabet-mezhdisciplinarnyy (дата обращения 17.07.2023 / access date 07/17/2023).
  8. IDF Diabetes Atlas; 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas-8th-edition.html.
  9. Аметов А.С.; Демидова Т.Ю.; Кочергина И.И. Эффективность препаратов метформина в лечении сахарного диабета 2-го типа. Медицинский совет. 2016;(3):30–7. [Ametov A.S.; Demidova T.Yu.; Kochergina I.I. The effectiveness of metformin drugs in the treatment of type 2 diabetes mellitus. Meditsinskiy sovet. 2016;(3):30–7. (In Russ.)]. doi: 10.21518/2079-701X-2016-3-30-37.
  10. Журтова И.Б.; Губачикова А.М.; Таова М.С.; Хачмахова Э.З. Дозозависимое влияние метформина на течение и исход новой короновирусной инфекции у пациентов с СД 2типа и ожирением. Актуальные вопросы медицины. Материалы 53-й научно-практической конференции студентов; аспирантов и молодых ученых. 2023. С. 21–4. [Zhurtova I.B.; Gubachikova A.M.; Taova M.S.; Khachmakhova E.Z. Dose-dependent effect of metformin on the course and outcome of a new coronavirus infection in patients with type 2 diabetes and obesity. Current issues in medicine. Materials of the 53rd scientific and practical conference of students; graduate students and young scientists. 2023. P. 21–4. (In Russ.)].
  11. Давыдов А.Л. Влияние метформина и манинила на показатели липидного обмена у больных сахарным диабетом типа 2. Проблемы эндокринологии. 2000;46(3):10–3. [Davydov A.L. The influence of metformin and maninil on lipid metabolism in patients with type 2 diabetes mellitus. Problemy endokrinologii. 2000;46(3):10–3. (In Russ.)].
  12. Bramante C.T.; Ingraham N.E.; Murray T.A.; et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2(1):e34–41. doi: 10.1016/S2666-7568(20)30033-7.
  13. Мкртумян А.М. Метформин – общепризнанный препарат первого выбора у больных сахарным диабетом 2-го типа. Медицинский совет. 2018;(4):20–7. [Mkrtumyan A.M. Metformin is a generally accepted drug of first choice in patients with type 2 diabetes mellitus. Meditsinskiy sovet. 2018;(4):20–7. (In Russ.)]. doi: 10.21518/2079-701X-20184-20-27.
  14. Diabetes Prevention Program Research Group. Diab Care. 2005;28:888–94.
  15. Diabetes Prevention Program Outcomes Study Research Group: prepared on behalf of the DPPOS Research Group. Diab Med. 2013;30(1):46–55.
  16. Мохорт Т.В. Метформин: реальные и потенциальные клинические сценарии. Медицинские новости. 2019;11:20–8. [Mokhort T.V. Metformin: real and potential clinical scenarios. Meditsinskiye novosti. 2019;11:20–8. (In Russ.)].
  17. Mary A.; Hartemann A.; Liabeuf S.; et al. Cardiovasc Diabetol. 2017;16(1):24.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2023
##common.cookie##